Justin F. Klamerus named EVP, chief medical officer at McLaren Health Care

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Justin F. Klamerus was named executive vice president and chief medical officer at McLaren Health Care. 

He will assume the position previously held by Michael McKenna, McLaren Health Care’s first CMO, who died in May 2022.

Klamerus has served as president of Karmanos Cancer Hospital and Network, a subsidiary of McLaren Health Care, since January 2017.

Klamerus’ history with McLaren began in 2009. He served as the program director of cancer services at McLaren Northern Michigan in Petoskey, MI, before becoming president of the McLaren Cancer Institute. In 2014, when McLaren acquired the Karmanos Cancer Institute, he assumed the role of executive vice president and chief quality officer at Karmanos. He was then named president of the organization.

While at Karmanos, Klamerus oversaw the expansion of the Karmanos Cancer Network and led business and clinical partnerships with community physicians, academic faculty, and graduate medical education partners.

In 2020, Klamerus was appointed to the Public Health Advisory Commission by Michigan Governor Gretchen Whitmer.

Table of Contents

YOU MAY BE INTERESTED IN

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login